skip to main content

Fibrate-Statin Combination Evidence — EECC MCQ

Instant feedback + full explanation. One question, done properly.

ModerateHypertension & Preventive CardiologyFibrate-Statin Combination EvidenceEECC

A 65-year-old man with established ASCVD and elevated triglycerides (TG 3.2 mmol/L) on statin is considered for fibrate therapy. What does the evidence show for adding a fibrate to a statin?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Fibrate-statin combination did not reduce cardiovascular events in the ACCORD-Lipid trial; fibrates are not routinely recommended for CVD risk reduction when added to statins

The ACCORD-Lipid trial (2010) demonstrated that adding fenofibrate to simvastatin in type 2 diabetes did not reduce cardiovascular events (though a subgroup with high TG and low HDL-C showed a possible benefit). The PROMINENT trial (2022) of pemafibrate (a selective PPAR-alpha modulator) also showed no CV benefit despite TG reduction. The ESC/EAS Dyslipidaemia Guidelines position fibrates as second-line for hypertriglyceridaemia management (primarily for very high TG >10 mmol/L to prevent pancreatitis). For residual CV risk from elevated TG in statin-treated patients, icosapent ethyl (REDUCE-IT) is preferred. Combination statin-fibrate increases myopathy risk (particularly with gemfibrozil — fenofibrate is the safer combination partner).

Reference: ESC/EAS (2019/2025): Dyslipidaemia Guidelines; ACCORD/PROMINENT Trials